Comera Life Sciences Holdings, Inc.

OTCPK:CMRA Stock Report

Market Cap: US$6.1k

Comera Life Sciences Holdings Past Earnings Performance

Past criteria checks 0/6

Comera Life Sciences Holdings has been growing earnings at an average annual rate of 46.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 81.8% per year.

Key information

46.1%

Earnings growth rate

82.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate81.8%
Return on equity-8,809.8%
Net Margin-935.0%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Comera Life Sciences rises on positive preclinical data from Sequrus study

Oct 18

Comera life sciences expands woburn operations

Oct 04

Comera Life Sciences announces up to $15M purchase agreement with Arena

Aug 31

Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M

Aug 10

Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans

May 27
Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown

How Comera Life Sciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:CMRA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 231-971
30 Jun 231-1081
31 Mar 231-18101
31 Dec 221-1892
30 Sep 221-17102
30 Jun 220-1581
31 Mar 220-862
31 Dec 210-542
31 Dec 200-211

Quality Earnings: CMRA is currently unprofitable.

Growing Profit Margin: CMRA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CMRA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CMRA has a negative Return on Equity (-8809.78%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies